Anti-influenza formulations and methods
AssigneePulmatrix, Inc.
InventorsRichard Batycky, David L. Hava, Robert W. Clarke, Michal M. Lipp
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.
Claims26
A pharmaceutical composition comprising an effective amount of a calcium salt and an effective amount of an anti-influenza agent, wherein the anti-influenza agent is selected from the group consisting of an NAI, an M2 channel inhibitor, an IMP dehydrogenase inhibitor, an influenza RNA polymerase inhibitor, a sialidase, a sialidase fusion protein, a sialyl multimer or polymer, a siRNA that targets expression of influenza genes, an oligonucleotide that targets expression of influenza genes, interferon alpha, an interferon inducer, and a signal transduction inhibitor, and further wherein the composition is suitable for administration to the respiratory tract and the effective amount of the calcium salt and the effective amount of the anti-influenza agent are synergistic.
(canceled)
(canceled)
12-15. (canceled)
(canceled)
22-43. (canceled)
(canceled)
47-50. (canceled)
A method for treating influenza-like illness comprising administering to an individual in need thereof an effective amount of a calcium salt formulation.
A method for the prophylaxis of influenza-like illness comprising administering to an individual at risk for infection by influenza-like illness an effective amount of a calcium salt formulation, wherein the calcium salt composition is administered to the respiratory tract.
53-54. (canceled)
Dependencies are inferred from the claim text.